John Stuelpnagel

John joined the Venrock family in 1998, shortly after co-founding Illumina (Nasdaq: ILMN) and convincing Bryan to make it his first investment. John was Illumina’s first CEO, and most recently its COO. After leaving Illumina, John co-founded Ariosa (a Venrock portfolio company), serving as its Executive Chairman until its acquisition by Roche. In addition, John was the Chairman at Sequenta until its acquisition by Adaptive (Nasdaq: ADPT). Currently, John is Chairman at the following Venrock portfolio companies: 10x Genomics (Nasdaq: TXG), Inscripta, and Element Biosciences, and also serves on the Board of Directors for Encoded Therapeutics. He is also the Chairman at Fabric Genomics.

John has a BS and a DVM from the University of California, Davis and an MBA from the University of Los Angeles.